Numerous preclinical studies in vitro and in vivo have evaluated the use of CAR-T cells armed to specifically target TAs in BC, with HER2-CAR constructs attracting the most attention and achieving robust tumor regressions (48–60). This evidence concerns the gene ERBB2 and neoplasm.